Biodel
CompanyUnited StatesFounded 2003
Biodel develops one asset, in phase 2 (VIAject in diabetes mellitus). Mostly protein or enzyme acting on Insulin/IGF-1 signalling, glycolysis and INSR; based in the United States, founded in 2003.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 0
- Signals
Pipeline
1Recombinant human insulin analog that binds to the insulin receptor to regulate glucose metabolism
Phase 2, Protein or enzyme, Insulin/IGF-1 signalling, Glycolysis, diabetes mellitus
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Trials1
- Similar companies6